# PanDox: Targeted Doxorubicin in Pancreatic Tumours

> **NCT04852367** · PHASE1 · WITHDRAWN · sponsor: **University of Oxford**

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer Stage IV
- Pancreatic Cancer Non-resectable
- Pancreatic Cancer Metastatic

## Interventions

- **DEVICE:** Focused Ultrasound
- **DRUG:** Doxorubicin
- **DRUG:** ThermoDox

## Key facts

- **NCT ID:** NCT04852367
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06-16
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of recruitment
- **Last updated:** 2023-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04852367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04852367, "PanDox: Targeted Doxorubicin in Pancreatic Tumours". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04852367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*